Skip to main content
. 2012 Jul;14(7):624–633. doi: 10.1593/neo.12486

Figure 3.

Figure 3

Celecoxib in combination with chemotherapy induces tumor regression of chemoresistant CRCs in vivo. Mice with MIP101, MIP/5-FU, and MIP/CPT tumor xenografts were treated with saline (control) or with different drug combinations followed by measurement of tumor size twice per week for a total of 36 days. Percent change in tumor size was calculated with respect to the size of the tumor before treatment. Results represent data averaged from data obtained from four to eight mice per group. Statistical significance: *P < .05 in comparison to saline-treated controls; blue arrow, P < .05 in comparison to single treatments (celecoxib, 5-FU or CPT-11).